Budesonide is an orally administered steroid, produced by AstraZeneca, which is released in the intestine, where it works locally and topically to decrease inflammation.
Patients taking budesonide experience fewer of the typical side-effects associated with other steroids used to treat Crohn's Disease, such as prednisone or prednisolone tablets. This is because most budesonide is not absorbed into the body.
| Budesonide produces fewer side-effects than other steroids.
Prior to approval, budesonide was studied in 651 patients with active Crohn's disease.
Patients treated with budesonide experienced significant improvement in their symptoms.
In the patients studied, the most common adverse events associated with budesonide were headache, respiratory infection, and nausea.
In addition, fewer patients receiving budesonide experienced facial swelling and acne than those receiving prednisolone.